New results describe development of DC cancer vaccine with enhanced immunogenic potential

NewsGuard 100/100 Score

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and collaborators at Radboud University Nijmegen Medical Centre in the Netherlands announced today that they have published new pre-clinical results in the journal Cancer Immunology Immunotherapy (doi:10.1007/s00262-012-1334-1) describing the development of a dendritic cell (DC) cancer vaccine with enhanced immunogenic potential. The findings show that ex vivo RNAi targeting of the programmed death ligands (PD-L1 and PD-L2) can significantly boost the immunogenicity of DC-based vaccines. These results could lead to the development of improved cellular vaccine therapies for the treatment of cancer and chronic viral infections.    

"At Alnylam, we continue to pioneer broad applications of RNAi in biotechnology and human health, while our core focus remains the advancement of RNAi therapeutics in our 'Alnylam 5x15' product strategy," said Rachel Meyers, Ph.D., Vice President, Research and RNAi Lead Development. "These new results demonstrate the potential of an ex vivo RNAi approach to strongly improve the immunogenicity of dendritic cell vaccines toward tumor antigens. As such, this new strategy could significantly enhance the potency of cellular immune therapy in cancer, and potentially other indications such as infectious disease."

"While much progress has been made in the development of dendritic cell vaccines in cancer, there is a clear need to improve this strategy for increased clinical benefit. Specifically, further advancement of dendritic cell therapies requires an enhanced potency of the T-cell anti-tumor responses," said Harry Dolstra, Ph.D., Associate Professor at Radboud University Nijmegen Medical Centre, Laboratory of Hematology. "These new findings show that a relatively simple ex vivo RNAi approach may be able to boost the effectiveness of cellular therapies in the treatment of cancer, and possibly chronic viral infections. We look forward to advancing this novel approach in clinical studies."

The new results describe development of a clinical-grade DC vaccine with improved immunogenic potential. Potent siRNA were designed and synthesized toward PD-L1 and PD-L2, key co-inhibitory proteins expressed on antigen-presenting cells that strongly limit activation of T-cells needed for a potent immune response to the tumor. Specifically, lipid nanoparticle (LNP)-formulated siRNA targeting PD-L1 and PD-L2 mediated efficient and specific silencing of PD-L1 and PD-L2 expression on human monocyte-derived DC isolated from healthy donors. Ex vivo treatment with siRNA was well tolerated by the isolated DC, with no measurable effect on phenotype or migratory capacity. Further, siRNA-treated DC were loaded by electroporation with mRNA encoding minor histocompatibility antigen (MiHA) to allow long-lasting presentation of antigenic peptides expressed by malignant cells. The combined LNP siRNA transfection electroporation protocol was found to be well tolerated by the isolated DC. The resulting PD-L silenced, MiHA-expressing DCs were shown to have a significantly enhanced ability to stimulate antigen-specific CD8+ T cell responses in cells from transplanted cancer patients ex vivo. This novel RNAi approach has potential implications for the treatment of cancer and chronic viral infections, where an improvement in DC vaccine potency is needed.


  1. JJ JJ Australia says:

    Gradalis Inc. in Texas have shown a survival advantage x 5 compared to controls in humans in a phase I clinical trial using RNAi in various advanced cancers, with 7 patients still alive after 2 - 3 years.  They are currently conducting three phase 2 clinical trials and seeing similar results.  These trials use expressed RNAi (shRNA) instead of siRNA, that Alnylam focus on.   The expressed RNAi foundation patents are owned by Benitec Biopharma in Australia, who last year combined RNAi in dentritic cells to target arthritis, showing excellent results in mice.   Thousands of pre-clinical in-vivo and ex-vivo studies published using shRNA without the delivery problems encountered by siRNA.  With a market cap of 1/60th of Alnylam, and equally important IP, they appear very under the radar.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Tiny DNA circles are key drivers of cancer formation, study suggests